ArticleFrontiers in endocrinology2025
TAS1R3 influences GTPase-dependent signaling in human islet β-cells.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TAS1R3 Regulates GTPase Signaling in Human Skeletal Muscle Cells for Glucose Uptake.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: The taste receptor type 1 member 3 (TAS1R3), a G protein-coupled receptor (GPCR), is expressed in pancreatic islet β-cells where it may influence intracellular signaling pathways critical for β-cell function. Although TAS1R3 is known to couple to heterotrimeric G-proteins, its potential influence on small GTPases-key regulators of vesicle trafficking, cytoskeletal remodeling, and signal transduction-remains unexplored. Investigating how TAS1R3 modulates small GTPase activity could uncover mechanisms by which β cells regulate insulin secretion and adapt to metabolic cues. Objective: We questioned whether activation of endogenous TAS1R3 in human islets or clonal human β-cells are necessary for glucose-stimulated insulin secretion Methods and results: We found that pharmacological TAS1R3 inhibition (lactisole) in human islets and a human β-cell line diminished glucose-stimulated insulin secretion, attenuated Src family tyrosine kinase signaling, and small GTPase Cdc42 activation. We excluded the requirement for the G protein Gαq/11 in TAS1R3 signaling by using the Gαq/11-specific YM-254890 inhibitor in β-cells. Notably, the significant reduction of TAS1R3 mRNA and protein levels in human type 2 diabetes pancreatic islets, which could be replicated in otherwise healthy cells exposed to diabetogenic stimuli, indicates that the TAS1R3 deficit may be a consequence of diabetogenic stimuli. Conclusion: Overall, our results suggest that TAS1R3 plays an essential role in GTPase signaling in islet β-cells adding to the growing list of proteins that play a vital role in islets as therapeutic targets in type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.